Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous and Subcutaneous): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3270
- Pages: 220
-
Format:
Immunoglobulin Market Overview:
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Immunoglobulin Key Market Segments:
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy
Primary Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain-Barre Syndrome
Others
By Product
IgG
IgA
IgM
IgE
IgD
By Mode of Delivery
Intravenous
5% Concentration
10% Concentration
Others
Sucutaneous
16.5% Concentration
20% Concentration
Others
By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Austria
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
Brazil
Turkey
Argentina
Rest of LAMEA
Key Players Profiled
Baxter international Inc.
CSL Ltd.
Grifols S.A.
Octapharma AG
Kedrion Biopharma Inc.
LFB group
Biotest AG
China Biologics Products, Inc.
Shire Plc.(Baxalta)
Bayer AG
The other players of the immunoglobulin market include (companies not profiled in the report):
Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Behring GmbH
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
BioScrip, Inc
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of immunodeficiency diseases
3.5.1.2. Increase in adoption of immunoglobulin
3.5.1.3. Increase in incidence of bleeding disorders
3.5.1.4. Surge in geriatric population
3.5.2. Restraints
3.5.2.1. Stringent government regulations
3.5.2.2. High cost of therapy
3.5.3. Opportunities
3.5.3.1. Opportunities in emerging economies
3.5.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Idiopathic thrombocytopenic purpura
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.2. Key market trends
5.1.3. Clinical interpretations
5.1.4. IGA
5.1.5. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGM
5.1.8. Key Market Trends
5.1.9. Clinical interpretation
5.1.10. IGE
5.1.11. Key Market Trend
5.1.12. Clinical interpretation
5.1.13. IGD
5.1.14. Key Market Trends
5.1.15. Clinical interpretation
CHAPTER 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
6.1. Overview
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Key Market Trends
6.2.2. Market size and forecast
6.2.2.1. 5% concentration
6.2.3. Market size and forecast
6.2.3.1. 10% Concentration
6.2.4. Market size and forecast
6.2.4.1. Other Concentrations
6.2.5. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Key Market Trends
6.3.2. Market size and forecast
6.3.2.1. 5% Concentration
6.3.3. Market size and forecast
6.3.3.1. 16.5% Concentration
6.3.4. Market size and forecast
6.3.4.1. 20% Concentration
6.3.5. Market size and forecast
6.3.5.1. Other Concentration
6.3.6. Market size and forecast
CHAPTER 7: IMMUNOGLOBULIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size & forecast, by country
7.2.3. North America market size & forecast, by application
7.2.4. North America market size & forecast, by mode of delivery
7.2.4.1. U.S. market size & forecast
7.2.4.2. Canada market size & forecast
7.2.4.3. Mexico market size & forecast
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size & forecast for immunoglobulin market, by country
7.3.3. Europe market size & forecast, by application
7.3.4. Europe market size & forecast, by mode of delivery
7.3.4.1. Germany market size & forecast
7.3.4.2. France market size & forecast
7.3.4.3. UK market size & forecast
7.3.4.4. Italy market size & forecast
7.3.4.5. Spain market size & forecast
7.3.4.6. Russia market size & forecast
7.3.4.7. Rest of Europe market size & forecast
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size & forecast, by country
7.4.3. Asia-Pacific market size & forecast, by application
7.4.4. Asia-Pacific market size & forecast, by mode of delivery
7.4.4.1. Japan market size & forecast
7.4.4.2. China market size & forecast
7.4.4.3. India market size & forecast
7.4.4.4. Australia market size & forecast
7.4.4.5. South Korea market size & forecast
7.4.4.6. Taiwan market size & forecast
7.4.4.7. Rest of Asia-Pacific market size & forecast
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. LAMEA market size & forecast, by country
7.5.3. LAMEA market size & forecast, by application
7.5.4. LAMEA market size & forecast, by mode of delivery
7.5.4.1. Brazil market size & forecast
7.5.4.2. South Africa market size & forecast
7.5.4.3. Saudi Arabia market size & forecast
7.5.4.4. Argentina market size & forecast
7.5.4.5. Rest of LAMEA market size & forecast
CHAPTER 8: COMPANY PROFILES
8.1. Baxter International Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Biotest AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. CSL Limited
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Grifols S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. LFB SA (LFB Biotechnologies SAS)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Octapharma AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Bayer AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. Kedrion Biopharma Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Shire Plc.(Baxalta)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. China Biologic Products, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
